Comparison of vancomycin and cefuroxime for infection prophylaxis in coronary artery bypass surgery

Infection Control and Hospital Epidemiology

Volumn 19, Issue 4, 1998, Pages 234-239

  Vuorisalo, Sailaritta ^a,c   Pokela, Risto ^a   Syrjälä, Hannu ^b  

^a UNIVERSITY OF OULU   (Finland)

^b OULU UNIVERSITY HOSPITAL   (Finland)

^c Central Hospital of Pori   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; VANCOMYCIN;

AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY ARTERY BYPASS GRAFT; FEMALE; FINLAND; HOSPITAL DEPARTMENT; HUMAN; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; SURGICAL INFECTION;

AGED; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; CEFUROXIME; CEPHALOSPORINS; CORONARY ARTERY BYPASS; FEMALE; FINLAND; HUMANS; MALE; MIDDLE AGED; SURGERY DEPARTMENT, HOSPITAL; SURGICAL WOUND INFECTION; VANCOMYCIN;

EID: 0032040728     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.2307/30142413     Document Type: Article

References (39)

1. Antimicrobial prophylaxis in surgery. Med Lett Drugs Ther 1993;35:91-94.
2. Nichols RL. Surgical antibiotic prophylaxis. Med Clin North Am 1995;79:509-522.
3. Kreter B, Woods M. Antibiotic prophylaxis for cardiothoracic operations. J Thorac Cardiovasc Surg 1992;104:590-599.
4. Boyce JM. Vancomycin-resistant enterococci: pervasive and persistent pathogens. Infect Control Hosp Epidemiol 1995;16:676-679.
5. Edmond MB, Ober JF, Weinbaum DL, Pfaller MA, Hwang T, Sanford MD, et al. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis 1995;20:1126-1133.
6. Hospital Infection Control Advisory Committee, Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 1995;16:105-113.
7. Lam S, Singer C, Tucci V, Morthland VH, Pfaller MA, Isenberg HD. The challenge of vancomycin-resistant enterococci: a clinical and epidemiologic study. Am J Infect Control 1995;23: 170-180.
8. Montecalvo MA, de Lencastre H, Carraher M, Gedris C, Chung M, VanHorn K, et al. Natural history of colonization with vancomycin-resistant Enterococcus faecium. Infect Control Hosp Epidemiol 1995;16:680-685.
9. Morris JG Jr, Shay DK, Hebden JN, McCarter RJ Jr, Perdue BE, Jarvis W, et al. Enterococci resistant to multiple antimicrobial agents, including vancomycin. Ann Intern Med 1995;123:250-259.
10. Murray BE. Editorial response: what can we do about vancomycin-resistant enterococci? Clin Infect Dis 1995;20:1134-1136.
11. Waldvogel FA, Vaudaux PE, Pittet D, Lew PD. Perioperative antibiotic prophylaxis of wound and foreign body infections: microbial factors affecting efficacy. Rev Infect Dis 1991;13(suppl 10):S782-S789.
12. Ehrenkranz NJ. Antimicrobial prophylaxis in surgery: mechanisms, misconceptions, and mischief. Infect Control Hosp Epidemiol 1993;14:99-106.
13. Koot MJ, Ijdenberg FN, Stuurman RM, Poell J, Bras LJ, Langemeijer JJM, et al. High pressure liquid chromatographic analysis of the serum concentration of cefuroxime after an intravenous bolus injection of cefuroxime in patients with a coronary artery bypass grafting. Pharm Weekbl Sci 1992;14:360-364.
14. Nooyen SMH, Overbeek BP, Brutel de la Rivière, Storm AJ, Langemeyer JJM. Prospective randomised comparison of single-dose versus multiple-dose cefuroxime for prophylaxis in coronary artery bypass grafting. Eur J Clin Microbiol Infect Dis 1994;13:1033-1037.
15. Levy JH, Kettlekamp N, Goertz P, Hermens J, Hirshman CA. Histamine release by vancomycin: a mechanism for hypotension in man. Anesthesiology 1987;67:122-125.
16. Southorn PA, Plevak DJ, Wright AJ, Wilson WR. Adverse effects of vancomycin administered in the perioperative period. Mayo Clin Proc 1986;61:721-724.
17. Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG. CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. Infect Control Hosp Epidemiol 1992;13:606-608.
18. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988;16:128-140.
19. Vuorisalo S, Pokela R, Syrjälä H. Is single-dose antibiotic prophylaxis sufficient for coronary artery bypass surgery? An analysis of peri-and postoperative serum cefuroxime and vancomycin levels. J Hosp Infect In press.
20. Brown GW. Sample size. Am J Dis Child 1988;142:1213-1215.
21. Gaynes R, Marosok R, Mowry-Hanley J, Laughlin C, Foley K, Friedman C, et al. Mediastinitis following coronary artery bypass surgery: a 3-year review. J Infect Dis 1991;163:117-121.
22. Sisto T, Laurikka J, Tarkka MR. Ceftriaxone vs cefuroxime for infection prophylaxis in coronary bypass surgery. Scand J Thorac Cardiovasc Surg 1994;28:143-148.
23. Slaughter MS, Olson MM, Lee JT Jr, Ward HB. A fifteen-year wound surveillance study after coronary artery bypass. Ann Thorac Surg 1993;56:1063-1068.
24. Nishida H, Grooters RK, Soltanzadeh H, Thieman KC, Schneider RF, Kim W-P. Discriminate use of electrocautery on the median sternotomy incision. J Thorac Cardiovasc Surg 1991;101:488-494.
25. Dineen P. The effect of suture material on the development of vascular infections. Vascular Surgery 1977;11:29-33.
26. Katz SV, Izhar M, Mirelman D. Bacterial adherence to surgical sutures: a possible factor in suture-induced infection. Ann Surg 1981;194:35-41.
27. Wilson APR. Surveillance of wound infections. J Hosp Infect 1995;29:81-86.
28. Byrne DJ, Lynch W, Napier A, Davey P, Malek M, Cuschieri A. Wound infection rates: the importance of definition and post-discharge wound surveillance. J Hosp Infect 1994;26:37-43.
29. Peterson CD, Lake KD, Arom KV, Love KR. Antibiotic prophylaxis in open-heart surgery patients: comparison of cefamandole and cefuroxime. Drug Intelligence and Clinical Pharmacy 1987;21:728-732.
30. Conklin CM, Gray RJ, Neilson D, Wong P, Tomita DK, Matloff JM. Determinants of wound infection incidence after isolated coronary artery bypass surgery in patients randomized to receive prophylactic cefuroxime or cefazolin. Ann Thorac Surg 1988;46:172-177.
31. Ehrenkranz NJ, Richter EI, Phillips PM, Schultz JM. An apparent excess of operative site infections: analyses to evaluate false-positive diagnoses. Infect Control Hosp Epidemiol 1995;16:712-716.
32. Taylor G, McKenzie M, Kirkland T, Wiens R. Effect of surgeon's diagnosis on surgical wound infection rates. Am J Infect Control 1990;18:295-299.
33. L'Ecuyer PB, Murphy D, Little JR, Fraser VJ. The epidemiology of chest and leg wound infections following cardiothoracic surgery. Clin Infect Dis 1996;22:424-429.
34. Brown RB, Bradley S, Opitz E, Cipriani D, Pieczarka R, Sands M. Surgical wound infections documented after hospital discharge. Am J Infect Control 1987;15:54-58.
35. Olson MM, Lee JT Jr. Continuous, 10-year wound infection surveillance. Arch Surg 1990;125:794-803.
36. Holtz TH, Wenzel RP. Postdischarge surveillance for nosocomial wound infection: a brief review and commentary. Am J Infect Control 1992;20:206-213.
37. Sands K, Vineyard G, Platt R. Surgical site infections occurring after hospital discharge. Surgical site infections occurring after hospital discharge. J Infect Dis 1996;173:963-970.
38. Hirschhorn LR, Currier JS, Platt R. Electronic surveillance of antibiotic exposure and coded discharge diagnoses as indicators of postoperative infection and other quality assurance measures. Infect Control Hosp Epidemiol 1993;14:21-28.
39. Yokoe DS, Platt R. Surveillance for surgical site infections: the uses of antibiotic exposure. Infect Control Hosp Epidemiol 1994;15:717-723.